Beamtree Holdings Ltd · ASX:BMT
Beamtree — Shareholder Meeting (November 2023)
28 slides from Beamtree's shareholder meeting presentation, Nov 21, 2023
Slide 1: Annual General Meeting – Chairman and CEO Address
Beamtree Holdings Limited (ASX: BMT) ASX Announcement Sydney, 21 November 2023 Annual General Meeting – Chairman and CEO Address The Board of Beamtree Holdings Limited (ASX: BMT) (“Beamtree” or the “Company”), a leading provider of AI decision support and data insights solutions, advises that the 20
Slide 2: Chairman and CEO Address to the AGM
Beamtree Holdings Limited (ASX: BMT) ASX Announcement Sydney, 21 November 2023 Chairman and CEO Address to the AGM Introduction Good morning, ladies and gentlemen. Welcome to the 2023 Annual General Meeting for Beamtree Holdings Limited. It is 4.00pm, we have a quorum present, and I declare the meet
Slide 3: Continued pipeline wins and milestones
• Continued pipeline wins and milestones achieved in YTD Trading across all 4 core divisions (refer below); • International revenue growth was +50% pcp with geographic expansion achieved in target markets in Asia, Middle East, UK and Canada; • Public and Private Healthcare customer wins in Australia
Slide 4: Revenue growth across our Coding segment
Coding Assistance and Data Quality (“Coding”) (Products sold to Hospital customers such as PICQ, RISQ and coding applications) 8. Revenue growth across our Coding segment grew via strong renewals and price growth across our two core data quality products, PICQ® and RISQ™ in our core domestic markets
Slide 5: Outlook Re-affirmed with Strong Operating Momentum
Outlook Re-affirmed with Strong Operating Momentum across all Four Segments Overall, Beamtree continues to deliver solid revenue growth with organic growth of +23% in Q1 whilst carefully managing its cost base. The Company remains on track to deliver an operating profit in FY24. The sales pipeline,
Slide 6: Q1 FY23 Highlights
As a historical record, the following summary shows a pleasing continuation of progress across all four divisions of Beamtree for FY23. ____________________________________________________________________________________________________________ Diagnostic Technology: Q1 FY23 Highlights: 1. +29% reve
Slide 7: Q3 and Q4 FY23 Highlights
they believe these will make a significant impact and assist Beamtree to sell its products across the whole of the NHS. Q3 FY23 Highlights: 20. Ongoing investment in the ADI product upgrade to deliver an easy to integrate and easy to use product. 21. Trial now installed in a large Asia Pacific Hospi
Slide 8: Coding and Analytics FY23 highlights
information manager and coder teams for several hospitals in British Columbia, Canada as a baseline to support plans for automation of clinical record coding audit in the future. This is our first major project in North America and was awarded via a public procurement. 39. Rolled out material price
Slide 9: FY23 Annual General Meeting
FY23 Annual General Meeting 21 November 2023
Slide 10: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 21 November 2023. This presentation may contain statements that are, or may be deemed to be, forward looking s
Slide 11: AGM Agenda
AGM AGENDA 1. Chair’s address 2. CEO Update 3. Order of Business 4. Q&A 2
Slide 12: Board of Directors
Board of Directors Mike Hill Stephen Borness Emma Gray Chairman of the Board Non-Executive Director Non-Executive Director James Birch Brad Lancken Tim Kelsey Non-Executive Director Non-Executive Director Chief Executive Officer
Slide 13: CEO Update
CEO Update 1. Beamtree Strategy 2. FY23 Highlights Copyright © Beamtree Holdings Limited – All Rights Reserved 4
Slide 14: Beamtree Strategy
Beamtree Strategy Copyright © Beamtree Holdings Limited – All Rights Reserved 5
Slide 15: Creating a better future for health
Creating a better future for health As a global AI health technology company, we empower organisations to deliver exceptional patient care. We strive to create a better future for health by turning data into insights and action through automation. Copyright © Beamtree Holdings Limited – All Rights R
Slide 16: Beamtree is committed to supporting learning health systems
Beamtree is committed to supporting learning health systems Driving continuous improvement by better access to healthcare information – towards safety, quality and efficiency.
Slide 17: Our product segments
Our product segments Copyright © Beamtree Holdings Limited – All Rights Reserved 8
Slide 18: Key Areas, Key Products and What They Do
Key Areas, Key Products and What They Do Product/ Solutions Application Problem Solved ROI Pricing/Scale Leverages scarce clinical Clinical rules to automate expert decision Removes duplication for experts in Recurring resources through automating making in Diagnostics providing diagnostic resu
Slide 19: About Us
About Us 25+ years of experience Australian company with Supporting healthcare globally Cutting-edge use of AI and Australian IP machine learning Diagnostic Technology leaders Clinical Decision Support in acute Coding Assistance & Analytics & Knowledge care Data Quality Networks 10
Slide 20: The Problems We Help Solve
The Problems We Help Solve Tackle unwarranted Offer revenue Promote transparency Drive automation variation assurance Address equity Bridge knowledge gaps Increase efficiency, Improve quality of access and resource allocation reducing errors of data Copyright © Beamtree Holdings Limited – All Rights
Slide 21: FY23 Highlights
FY23 Highlights Copyright © Beamtree Holdings Limited – All Rights Reserved 12
Slide 22: FY23 Financial Highlights
FY23 Financial Highlights 25% PCP* 38% 78% 64% $8.8M PCP PCP PCP Annual recurring Reported International Operating Loss Cash Revenue Revenue Revenue $22.8M $22.8M* $7.3M $(1.4)M +$0.8M Operating cashflow *Reported recurring revenue growth +51% • Prior Corresponding Period “PCP” 13 Copyright © Beamtr
Slide 23: FY23 Divisional Highlights
FY23 Divisional Highlights Diagnostic Technology: AI Clinical Decision Support: Indirect Sales: via partnership with Abbott Laboratories Inc. Scientific endorsement of Beamtree AI in transforming patient safety • Dec 22 signed a new distribution partnership with Abbott. • ADI research published in ‘
Slide 24: FY23 Divisional Highlights
FY23 Divisional Highlights Coding Assistance and Data Quality Analytics and Knowledge Networks Audit & Advisory – lead generation toward product implementation Sales momentum • Saudi - awarded $1m health information management strategy • 45% of group revenue, +95% renewal rates contract alongside ou
Slide 25: FY24 YTD Trading
FY24 YTD Trading Diagnostic Technology: AI Clinical Decision Support: Indirect Sales via partnership with Abbott Laboratories Inc. • New ADI customer, Gold Coast Hospital and Health Service, signed in Q1 with aim of acting as a reference site for QLD • 3 new licences YTD (Greece, Mexico and Italy).
Slide 26: FY24 Outlook
FY24 Outlook Beamtree targeting to deliver a Management reaffirms long Targeting FY24 organic revenue Continued focus on cost positive operating profit in term outlook of delivering growth of +20% management with cost growth FY24 annual recurring revenue of % targeted to be lower than $60m by 2026 Q
Slide 27: Long Term Horizon – Reaffirm Conviction
Long Term Horizon – Reaffirm Conviction Main Drivers of Growth: ~70% of the growth will come from overseas market $22.8M FY23 18 Copyright © Beamtree Holdings Limited – All Rights Reserved
Slide 28: Thank you
Thank you Copyright © Beamtree Holdings Limited – All Rights Reserved 19
Beamtree Holdings — Shareholder Meeting (November 2023) on 6ix